Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial Prof Rohit Loomba, MDa Send email to roloomba@health.ucsd.edu ∙ Prof Jacob George, MBBSb ∙ Prof Laurent Castera, MDc,d ∙ Prof Sven Francque, MDe ∙ Prof Eric Lawitz, MDf ∙ Ahsan Shoeb, MDg ∙ et al.

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial Prof Rohit Loomba, MDa Send email to roloomba@health.ucsd.edu ∙ Prof Jacob George, MBBSb ∙ Prof Laurent Castera, MDc,d ∙ Prof Sven Francque, MDe ∙ Prof Eric Lawitz, MDf ∙ Ahsan Shoeb, MDg ∙ et al. https://www.thelancet.com/journals/langas/article/PIIS2468-1253(26)00123-8/fulltext?dgcid=raven_jbs_etoc_feature_langas